Forcing new Frontiers in Molecular Medicine


KCT is a limited company based in Kuopio, Finland that was founded in 2017. We undertake pioneering high-quality basic and translational research in the new and exciting area of Advanced Therapeutic Medicinal Products (ATMPs). Our scientific teams combine scientific know-how gained from years of experience in the sector and the latest technologies to research and develop gene and cell therapy products into Phase I human studies.

We undertake science in collaboration with academic groups all over the world and also have access to FinVector's GMP manufacturing facility in Finland as well as their quality and regulatory teams to ensure a product path from research to patients. KCT’s main therapeutic focuses are cancer and cardiovascular disease, but our scope of interest is not fixed and we also evaluate wider areas, such as neurological dysfunction, for other important therapy approaches.

You must approve to our use of cookies to view this content.

Board of directors

Jean-Frédéric Paulsen
Executive Chairman, Ferring Ventures SA
Member of the Board, Ferring Pharmaceuticals

Araz Raoof
President FRI & SVP Research Global Research & Development

Seppo Ylä-Herttuala
Professor University of Eastern Finland

Klaus Dugi
CEO, Vandria Therapeutics
Venture Partner, ND Capital
Former CMO of Ferring Pharmaceuticals


Jean Frédéric Paulsen

Managing Director

Tuija Kekarainen

Scientific Director

Olga Gurvich

Analytical Manager

Eevi Lipponen

Vector Platform Manager

Katja Sirviö

Cell Therapy Development Manager

Joonas Malinen

Laboratory Manager

Tiina Nieminen

Gene Therapy Development Manager